Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olof Bengtsson

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Cardiac Failure|December 17, 2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Karola Jering, Rudolf A DE Boer, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Circulation|July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFAlice M Jackson, Pooja Dewan, Inder S Anand, et al.
JAMA|March 29, 2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without DiabetesMark C Petrie, Subodh Verma, Kieran F Docherty, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Cardiac Failure|December 17, 2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Karola Jering, Rudolf A DE Boer, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
Circulation|July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFAlice M Jackson, Pooja Dewan, Inder S Anand, et al.
JAMA|March 29, 2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without DiabetesMark C Petrie, Subodh Verma, Kieran F Docherty, et al.
Pageof 8